ORMP · XBRL financial data

Oramed Pharmaceuticals financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ORMP's year ends in late December)

In thousands of dollars	FY 2020Aug 31, 2020	FY 2021Aug 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	2,710	2,703	2,703	1,340	—	2,000
Cost of revenue	—	—	—	—	—	1,987
Gross profit	—	—	—	—	—	13
Research and development	10,235	20,989	27,639	8,971	6,324	6,381
General and administrative	4,232	5,937	13,811	8,425	6,457	8,720
Operating income (loss)	(11,757)	(24,223)	(40,598)	(15,769)	(12,781)	(15,088)
Interest income	—	—	—	10	—	—
Interest expense	—	—	—	2,037	853	—
Other income (expense)	—	—	—	13	4	(606)
Income tax expense (benefit)	—	—	100	—	3,183	11,308
Net income (loss)	(11,511)	(22,989)	(36,561)	5,525	(19,103)	64,050
Earnings per share, basic USD per share	—	—	0.94	0.14	(0.48)	1.53
Earnings per share, diluted USD per share	—	—	0.94	0.14	(0.48)	1.50
Weighted average shares, basic thousands of shares	—	—	38,998	40,315	40,828	41,403
Weighted average shares, diluted thousands of shares	—	—	38,998	40,567	40,828	42,419

Fiscal years (ORMP's year ends in late December)

In thousands of dollars	FY 2020Aug 31, 2020	FY 2021Aug 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	19,296	77,245	40,464	9,055	54,420	45,947
Short-term investments	3,298	—	—	57,713	—	—
Marketable securities	9,544	5,851	3,743	1,807	3,441	5,417
Marketable securities, non-current	3,928	6,692	2,700	1,807	3,524	8,371
Prepaid and other current assets	611	—	1,389	537	1,291	2,741
Total current assets	40,511	95,337	157,109	162,584	143,221	133,271
Property and equipment, net	99	397	815	873	698	586
Right-of-use asset	75	533	987	694	414	750
Total assets	44,633	127,999	161,642	220,551	155,278	230,864
Accounts payable	—	—	—	551	789	443
Accrued liabilities	—	—	—	605	740	1,084
Total current liabilities	4,536	6,679	5,746	53,214	5,685	19,086
Lease liability, non-current	31	403	647	342	156	540
Accumulated deficit	(92,614)	(114,852)	(163,081)	(157,556)	(176,616)	(123,436)
Total stockholders' equity	32,879	115,773	151,812	163,821	146,265	199,744
Total liabilities and equity	44,633	127,999	161,642	220,551	155,278	230,864
Common shares outstanding (cover page) thousands of shares	23,676	38,086	39,784	40,519	40,850	40,446

Fiscal years (ORMP's year ends in late December)

In thousands of dollars	FY 2020Aug 31, 2020	FY 2021Aug 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(11,511)	(22,989)	(36,561)	5,525	(19,103)	64,050
Stock-based compensation	1,173	2,695	11,509	4,212	4,053	5,992
Net cash from operating activities	(12,440)	(21,181)	(27,918)	(10,295)	(8,412)	(9,145)
Purchases of property and equipment	82	375	496	254	18	9
Net cash from investing activities	4,626	(23,764)	30,211	(73,038)	105,817	5,443
Proceeds from issuing common stock	—	10,617	10,617	2,428	—	—
Share repurchases	—	—	—	—	2,484	4,741
Net cash from financing activities	23,786	102,892	10,779	51,978	(52,036)	(4,741)
Net change in cash	15,967	57,949	13,008	(31,409)	45,365	(8,473)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Oramed Pharmaceuticals	15,245	not reported	(200)*	41.6M	80.5 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	109,528	not reported	(4,515)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026
Inovio Pharmaceuticals	31,526	0	(18,047)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Macrogenics	113,907	32,832	(40,748)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Elicio Therapeutics	23,480	not reported	(8,165)*	26.3M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Coherus Oncology	82,923	not reported	(62,090)*	154.5M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2,800	399	(5,160)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43,287	29,105	(16,728)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Immunic	155,098	not reported	(30,998)*	13.6M	5.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.